Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

A 17β-Estradiol–Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women

A Randomized Controlled Trial

Lobo, Rogerio A.; Archer, David F.; Kagan, Risa; Kaunitz, Andrew M.; Constantine, Ginger D.; Pickar, James H.; Graham, Shelli; Bernick, Brian; Mirkin, Sebastian

Obstetrical & Gynecological Survey: November 2018 - Volume 73 - Issue 11 - p 630–632
doi: 10.1097/01.ogx.0000549834.30469.f2

(Abstracted from Obstet Gynecol 2018;132:161–170)

After the first publication of Women's Health Initiative findings in 2002, many women stopped taking US Food and Drug Administration (FDA)–approved, hormone therapy (HT) and started using non–FDA-approved, “natural” compounded HT believing that it was a safer option. In 2015, it was estimated that 1 million to 2.5 million US women used the unapproved, compounded HT.

Columbia University Medical Center, New York, NY; Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA; University of California, San Francisco, San Francisco; Sutter East Bay Medical Foundation, Berkeley, CA; University of Florida College of Medicine-Jacksonville, Jacksonville, FL; EndoRheum Consultants, LLC, Malvern, PA; and TherapeuticsMD, Boca Raton, FL

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.